Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.34 |
| ▸ | CCR5 | P51681 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16714152 | 0.94 | OPRM1 (0.38) | OGFRL1OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL852496 | 0.85 | OGFRL1 (0.53) | OGFRL1OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL854436 | 0.84 | OPRM1 (0.40) | OGFRL1OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL852255 | 0.73 | FKBP1A (0.40) | OPRM1OPRL1NPC1GAAMAPK1 | |
| SCHEMBL13221721 | 0.73 | OGFRL1 (0.74) | OGFRL1OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL550752 | 0.69 | OPRM1 (0.53) | OGFRL1OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL551433 | 0.68 | DDB1 (0.48) | FKBP1ADDB1CRBN | |
| SCHEMBL852258 | 0.67 | JAK2 (0.38) | OGFRL1OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL25554839 | 0.67 | TSHR (0.49) | — | |
| SCHEMBL3724255 | 0.65 | DDB1 (0.48) | HTR2CDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564240-A1 | PIPERIDINE INTERMEDIATES | Purdue Pharma L.P. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-3101018-A1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma L.P. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2433937-B1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160159785-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2016-06-09 | — | — | US | disclosed |
| EP-2086958-B1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8846929-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2433936-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159785-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, P2RX5, P2RX3 | OGFRL1 2120/4885OPRM1 25/4885OPRL1 11/4885 |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | P2RX4, P2RX5, P2RX3 | OGFRL1 2120/4885OPRM1 25/4885OPRL1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.